Pharmaceuticals
News Releases
2010
December
Pharmaceuticals
The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Corporate
Defendants Appeal From Final Judgment in U.S. Abilify® Patent Litigation
Pharmaceuticals
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14
Corporate
Tokushima Itano Factory Recognized Among "Corporate Greening Linked to Conservation of Biodiversity: Best 100" Sole factory manufacturing medical-use pharmaceuticals to receive recognition
Pharmaceuticals
Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
November
Corporate
Toward a Factory that is Friendly to Both the Environment and People The Tokushima Itano Factory Helps to Support the Asan Earth Festival in Itano to be Held on November 23, 2010
Pharmaceuticals
Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Corporate
Otsuka Prevails in U.S. Abilify® Patent Litigation
Nutraceuticals
Clinical tests in Japan demonstrate research results relating to the efficacy of "Ion supply drink" for dehydration after bathing
Pharmaceuticals
Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye
Pharmaceuticals
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
October
Pharmaceuticals
SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
Nutraceuticals
New Release of Medicated Skin Wash in 500mL Pump-style Economy Size and Refill Pouch Available from November 12, 2010
Pharmaceuticals
OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET
Corporate
OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
September
Nutraceuticals
Tweet Runners app for iPhone released on September 29th Tweet Runners and Amino-Value keep runners going
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
Pharmaceuticals
Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action Released on September 17
Pharmaceuticals
The Antiplatelet Agent Pletaal® (Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology
Nutraceuticals
Renewed Package Design for Nature Made America's number one-selling vitamin, mineral and supplement brand
Corporate
Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1
August
Corporate
Publication of Environmental and Social Report 2010 - Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs -
Corporate
21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010
July
Pharmaceuticals
E Keppra® (levetiracetam) receives regulatory approval in Japan
Nutraceuticals
Care for delicate neck and decolletage areas InnerSignal Rejuvenate Clear-up Mask debuts September 1, 2010
Pharmaceuticals
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
June
Corporate
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
Pharmaceuticals
Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 38.5 KB)
Pharmaceuticals
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
Otsuka Pharmaceutical to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceutical Information Tools
Nutraceuticals
A new style of “thoughtful gesture” Pocari Sweat Heartfelt Summer Letter Available at Post Offices throughout Japan from June 15
May
Pharmaceuticals
Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corporate
Indonesian affiliate PT. Amerta Indah Otsuka hosts May 26, 2010 dedication ceremony for Kejayan Factory - New Pocari Sweat production facility -
Nutraceuticals
Nature Made® Essential Nutrients for Modern Life Stlyes Introducing New Family Size Versions of Iron & Fish Oil（with EPA & DHA） Available from May 11, 2010
April
Corporate
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
Pharmaceuticals
First Antithrombotic Orally Disintegrating Tablets Antiplatelet Agent "Pletaal® OD Tablets" Launched on April 26
Corporate
Otsuka Pharmaceutical to Exhibit Soylution Concept Video in Japan Industry Pavilion at Expo 2010 Shanghai
Nutraceuticals
A Refreshing New Concept: Whole Soy + Carbonate Sparkling Soy Water, SOYSH Debuts
Pharmaceuticals
Groundbreaking Ceremony for New Plant to Manufacture Active Pharmaceutical Ingredients held on April 8 at Saga Factory
March
Corporate
First reader-participation collaboration OTSUKA Health Comic Library Sequel Vol. 3 “We Are Children of the Earth: The Environment & Our Health” March 31 publication for donation to elementary schools nationwide
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50
Pharmaceuticals
FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography
Pharmaceuticals
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Nutraceuticals
New Medicated Skin Wash from UL•OS Line of Men's Face & Body Care Available from April 22, 2010
Pharmaceuticals